ALVOTECH
Last · NASDAQ$5.17-0.21 (-3.90%)close · yahoo · 13h ago
Market cap$1.84B356.8M sh
P/E · TTM-8.3fwd 22.6 · eps -0.62 · loss
Beta0.20vs S&P 500
Div yield0.00%annual · TTM
52w range
$2.94$9.045
Volume1.0Msession
| Revenue | $586.3M |
|---|---|
| Operating income | $78.2M |
| Net income | $27.9M |
| Free cash flow | $-114.7M |
| Operating margin | 13.3% |
| Net margin | 4.8% |
| Period | 2025 |
Loading chart…
OpenFilings analyst
Our analyst
From latest 20-F · 2026-03-31
- Operating Cf Burn
- Cash Conversion Weak
Red flags
- Operating Cf Burn — Negative operating cash flow
- Cash Conversion Weak — Cash conversion (CFO/Rev) -8.6%
Upcoming earnings
9:00 PM UTC+1
Period
Sep 2026
Est. EPS
−$0.04
Est. revenue
163.1M
Earnings transcripts
- Issuer webcast
Open Link to registration form for webcast (live or replay)
ALVOTECH
- Issuer webcast
Open Link to registration form for webcast (live or replay)
ALVOTECH
- Issuer webcast
Open Link to registration form for webcast (live or replay)
ALVOTECH
- Issuer webcast
Registration for webcast (by invitation from UBS) Link
ALVOTECH
- Issuer webcast
Open Link to registration form for webcast (live or replay)
ALVOTECH
- Issuer webcast
Open Link to registration form for webcast (live or replay)
ALVOTECH
Press & signals
- GlobeNewswire
Alvotech and LOTTE Biologics announce US-based manufacturing agreement to increase global supply
- GlobeNewswire
Alvotech and LOTTE Biologics announce US-based manufacturing agreement to increase global supply
- GlobeNewswire
FDA approves additional U.S. manufacturing capacity for SIMLANDI®, Alvotech’s biosimilar to Humira®
The rest of this company's wire — with summaries and source links — is part of Pro.
See plans